224
Participants
Start Date
April 14, 2023
Primary Completion Date
November 28, 2023
Study Completion Date
November 28, 2023
GP40321
GP40321, solution for subcutaneous injection, 100 U/mL (GEROPHARM LLC, Russia)
Apidra® SoloStar®
Apidra® SoloStar®, solution for subcutaneous injection, 100 U/mL (Sanofi-Aventis Deutschland GmbH, Germany)
RinGlar®
Patients also receive long-acting basal insulin therapy (insulin glargine 100 U/mL) throughout the study
National Medical Research Center of Endocrinology of the Ministry of Health of the Russian Federation, Moscow
"Endocrinological Dispensary of the Moscow City Health Department", Moscow
Almazov National Medical Research Center of the Ministry of Health of the Russian Federation, Saint Petersburg
X7 Research, LLC, Saint Petersburg
City Multidisciplinary Hospital No. 2, Saint Petersburg
"City polyclinic No. 117", Saint Petersburg
St. Elizabeth City Hospital of the Holy Martyr, Saint Petersburg
"City polyclinic No. 112", Saint Petersburg
"City polyclinic No. 112", Saint Petersburg
"Eco-Safety Research Center, LLC", Saint Petersburg
City Pokrovskaya Hospital, Saint Petersburg
"City polyclinic No. 4", Saint Petersburg
Volgograd Regional Clinical Hospital No. 1, Volgograd
Interregional Clinical and Diagnostic Center, Kazan'
"Diabetes Center, LLC", Samara
RZD-Medicine Clinical Hospital of Chelyabinsk, Chelyabinsk
Krasnoyarsk State Medical University named after Professor V.F. Voino-Yasenetsky, Ministry of Health of the Russian Federation, Krasnoyarsk
Lead Sponsor
Geropharm
INDUSTRY